儿童慢性髓性白血病无治疗缓解:Tata纪念医院儿童CML队列的前瞻性研究
该前瞻性研究纳入45例慢性期儿童CML患者,按NCCN指南标准停药并每3个月qPCR监测,中位随访25个月,71.1%实现无治疗缓解,12和24个月无治疗缓解率分别为70%和66%,基线Treg水平较高与停药失败显著相关,过半患者停药2年后骨密度改善。
要点
- 45例慢性期儿童CML患者停用伊马替尼后71.1%(32/45)实现无治疗缓解,中位随访25个月。
- 无治疗缓解率12个月为70%、24个月为66%,5岁以下88.9%对比5岁以上61.8%(p=0.18)。
- 13例停药失败中11例在停药6个月内失去主要分子学反应,10例重启伊马替尼后中位3个月重获主要分子学反应。
核心结论
- 儿童CML可实现较高的无治疗缓解率,并对骨骼健康有额外获益。
- 较少频次的分子学监测未与不良结局相关,免疫系统似乎在维持无治疗缓解中起作用。
研究设计与样本
- 前瞻性研究,纳入45例慢性期儿童CML患者,均接受伊马替尼治疗。
- 停药资格按现行NCCN指南标准,qPCR监测频率为每3个月一次(较宽松)。
- 研究注册于印度临床试验注册中心(CTRI/2020/11/029199)。
主要发现
- 中位随访25个月(范围6-42个月),45例中32例(71.1%)无治疗缓解成功。
- 无治疗缓解率12个月为70%、24个月为66%。
- 5岁以下儿童无治疗缓解率88.9%,5岁以上为61.8%(p=0.18)。
- 13例停药失败患者中11例在停药6个月内失去主要分子学反应;主要分子学反应丧失的累积发生率6个月为26.4%、12个月为27%、24个月为33%。
- 13例停药失败中10例(76.9%)在重启伊马替尼后中位3个月(范围2-20个月)内重获主要分子学反应;基线Treg水平较高与停药失败显著相关(p=0.005)。
关键数值与推荐
- 停药资格按现行NCCN指南标准。
- qPCR监测每3个月一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%-3% of all childhood leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their long-term effects on growth and bone health in children. We prospectively studied treatment-free remission (TFR) in 45 children with pCML in chronic phase on imatinib. Eligibility criteria were as per current NCCN guidelines, with a less stringent qPCR monitoring scheduled every 3 months. TFR was successful in 71.1% (32 out of 45) of patients after a median follow-up of 25 (range: 6-42) months. The TFR rates at 12 and 24 months were 70% and 66%, respectively. Children under 5 years had a TFR rate of 88.9%, compared to 61.8% in those over 5 years (p = 0.18). Eleven of the 13 patients who lost MMR did so within 6 months of discontinuation. The cumulative incidence of loss in MMR at 6, 12, and 24 months was 26.4%, 27%, and 33%, respectively. Ten out of 13 (76.9%) patients with discontinuation failure (DF) regained MMR within 3 (2-20) months of restarting imatinib. A significant correlation was found between higher T-regulatory cell levels at baseline and DF (p = 0.005). More than half patients showed improved bone mineral density after 2 years of TFR. Our findings suggest that high TFR rates can be attained in pCML, with added benefits for bone health. Less frequent molecular monitoring was not associated with adverse outcomes and there seems to be a role of the immune system in sustaining TFR. The study is registered in the Clinical Trials Registry-India (CTRI/2020/11/029199).
引用
- Roy Moulik N, Keerthivasagam S, Chatterjee G, et al. Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort. Am J Hematol. 2024. PMID: 39568222. doi:10.1002/ajh.27528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。